Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Phospho-CD104 (Tyr1510) Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA540263
Description
This antibody is predicted to react with mouse and rat based on sequence homology.
Integrins are heterodimers comprised of alpha and beta subunits, that are noncovalently associated transmembrane glycoprotein receptors. Different combinations of alpha and beta polypeptides form complexes that vary in their ligand-binding specificities. Integrins mediate cell-matrix or cell-cell adhesion, and transduced signals that regulate gene expression and cell growth. This gene encodes the integrin beta 4 subunit, a receptor for the laminins. This subunit tends to associate with alpha 6 subunit and is likely to play a pivotal role in the biology of invasive carcinoma. Mutations in this gene are associated with epidermolysis bullosa with pyloric atresia. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.
Specifications
Phospho-CD104 (Tyr1510) | |
Polyclonal | |
Unconjugated | |
ITGB4 | |
AA407042; C230078O20; CD antigen CD104; CD104; CD104 antigen; GP150; integrin beta 4; integrin beta-4; integrin subunit beta 4; integrin, beta 4; Itgb4 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
192897, 25724, 3691 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
ELISA, Immunohistochemistry, Western Blot | |
1 mg/mL | |
PBS with 0.5% BSA, 50% glycerol and 0.02% sodium azide; pH 7.4 | |
A2A863, P16144, Q64632 | |
ITGB4 | |
Synthesized peptide derived from human Integrin beta4 around the phosphorylation site of Y1510. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction